tbuckley/cabot-search huggingface dataset:
Pulmonary arterial hypertension: screening challenges in systemic sclerosis and future directions
Authors: Nermin Diab, Paul M. Hassoun
Journal: European Respiratory Journal (2017)

Despite the advent of multiple medical therapies for pulmonary arterial hypertension (PAH), there is currently no cure available for this disease which continues to impose a very heavy burden of morbidity and mortality on afflicted patients. Survival on medical therapy is at best 7 years in patients with idiopathic PAH [1] and significantly less in patients with associated PAH (APAH), such as those with connective tissue disease (CTD) and particularly with scleroderma-associated PAH (SSc-PAH), where median survival is about 4 years. Screening for PAH is significant in scleroderma as it may lead to early diagnosis and initiation of therapy <http://ow.ly/TR6230aqRgq>
Determining association between activation of mTOR signal pathway and patient with malignant pleural mesothelioma who underwent a multimodality therapy including extrapleural pneumonectomy.
Authors: Ayumi Kuroda, Seiji Matsumoto, Toru Nakamichi, Shoko Monji, Masaki Hashimoto, Teruhisa Takuwa, Nobuyuki Kondo, Tohru Tsujimura, Takashi Nakano, Seiki Hasegawa
Journal: Journal of Clinical Oncology (2015)

e18543 Background: The mTOR signal pathways are activated in a broad range of malignancies. Methods: A multimodality therapy consisting of induction chemotherapy , extrapleural pneumonectomy (EPP) with/without radiation therapy (RT) was performed to 46 patients with malignant mesothelioma (MPM) at Hyogo College of Medicine, Nishinomiya, Japan from April 2004 to October 2012. Paraffin embedded surgical sample was used for immunohistochemistry to evaluate the expression of phospho- mTOR (p-mTOR) and phospho-S6 Ribosomal Protein (p-S6RP). Overall survival (OS) from the time of surgery was determined by Kaplan-Meier method and results were compared by log-rank test. Results: Of 46 patients, 20 had bimodality therapy and other 26 patients received trimodality therapy incluging RT. OS of 46 patients was 24.5 month. Conclusions: High expression of p-S6RP and p-mTOR was associated with better survival in MPM patients without undergoing RT. It was speculated that survival impacts of p-mTOR signal pathway was masked by RT. p-mTOR positive p-mTOR negative p Survival (month) 37.1 n = 18 10.0 n = 28 0.106 with RT 36.3 n = 10 53.7 n = 16 0.779 without RT 22.0 n = 8 6.0 n = 12 0.008 p-S6RP positive p-S6RP negative p Survival (month) 37.1 n = 32 10.0 n = 14 0.029 with RT 43.6 n = 21 Not reached n = 5 0.779 without RT 15.2 n = 11 5.0 n = 9 0.095
Aging and the immune response to organ transplantation
Authors: Monica M. Colvin, Candice A. Smith, Stefan G. Tullius, Daniel R. Goldstein
Journal: Journal of Clinical Investigation (2017)

An increasing number of older people receive organ transplants for various end-stage conditions. Although organ transplantation is an effective therapy for older patients (i.e., older than 65 years of age), such as in end-stage renal disease, this therapy has not been optimized for older patients because of our lack of understanding of the effect of aging and the immune response to organ transplantation. Here, we provide an overview of the impact of aging on both the allograft and the recipient and its effect on the immune response to organ transplantation. We describe what has been determined to date, discuss existing gaps in our knowledge, and make suggestions on necessary future studies to optimize organ transplantation for older people.
Vascular Endothelial Mitochondrial Function Predicts Death or Pulmonary Outcomes in Preterm Infants
Authors: Jegen Kandasamy, Nelida Olave, Scott W. Ballinger, Namasivayam Ambalavanan
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Vascular endothelial mitochondrial dysfunction contributes to the pathogenesis of several oxidant stress-associated disorders. Oxidant stress is a major contributor to the pathogenesis of bronchopulmonary dysplasia (BPD), a chronic lung disease of prematurity that often leads to sequelae in adult survivors.This study was conducted to identify whether differences in mitochondrial bioenergetic function and oxidant generation in human umbilical vein endothelial cells (HUVECs) obtained from extremely preterm infants were associated with risk for BPD or death before 36 weeks postmenstrual age.HUVEC oxygen consumption and superoxide and hydrogen peroxide generation were measured in 69 infants.Compared with HUVECs from infants who survived without BPD, HUVECs obtained from infants who developed BPD or died had a lower maximal oxygen consumption rate (mean ± SEM, 107 ± 8 vs. 235 ± 22 pmol/min/30,000 cells; P < 0.001), produced more superoxide after exposure to hyperoxia (mean ± SEM, 89,807 ± 16,616 vs. 162,706 ± 25,321 MitoSOX Red fluorescence units; P < 0.05), and released more hydrogen peroxide into the supernatant after hyperoxia exposure (mean ± SEM, 1,879 ± 278 vs. 842 ± 119 resorufin arbitrary fluorescence units; P < 0.001).Our results indicating that endothelial cells of premature infants who later develop BPD or die have impaired mitochondrial bioenergetic capacity and produce more oxidants at birth suggest that the vascular endothelial mitochondrial dysfunction seen at birth in these infants persists through their postnatal life and contributes to adverse pulmonary outcomes and increased early mortality.
Dithiophenes potentiate differentiation of APL cells by lowering the threshold for ligand mediated co-repressor/co-activator exchange with RAR alpha and enhancing changes in ATRA regulated gene expression.
Authors: K Xu, D Chung, A Glasow, Y K Jing, Fabien Guidez, K Stegmaier, T R Golub, A Zelent, S Waxman
Journal: Blood (2003)
Suppression of Luteinizing Hormone Enhances HSC Recovery after Hematopoietic Injuries
Authors: Enrico Velardi, Jennifer Jia-ying Tsai, Kimon V. Argyropoulos, Shieh Jae-Hung, Sophie Lieberman, Fabiana Kreines, Yusuke Shono, Lauren Young, Tobias Wertheimer, Robert R. Jenq, Alan M Hanash, Malcolm A.S. Moore, Marcel Van Den Brink, Jarrod A Dudakov
Journal: Blood (2016)
Soluble Axl identifies patients at higher risk for hepatocellular carcinoma development: results from a large scale multicenter analysis
Authors: M. Dengler, K. Staufer, H. Huber, R. Stauber, H. Bantel, K.H. Weiss, P. Starlinger, H. Pock, P. Klöters-Plachky, D.N. Gotthardt, P. Rauch, C. Lackner, J. Stift, C. Brostjan, T. Gruenberger, T. Kumada, H. Toyoda, T. Tada, T.S. Weiss, M. Trauner, W. Mikulits
Journal: Journal of Hepatology (2017)
In vitro and in vivo characterization of the selective toll-like receptor 8 agonist GS-9688
Authors: S. Daffis, D. Ramakrishnan, C. Niu, J. Zheng, R. Santos, M. Mish, G. Chin, V. Aktoudianakis, S. Metobo, H.-J. Pyun, H. Yu, G. Lee, A. Palazzo, C. Frey, S. Pflanz, W.E. Delaney, S.P. Fletcher, R. Mackman
Journal: Journal of Hepatology (2017)
Solithromycin treatment for 13 weeks improves histological parameters in nonalcoholic steatohepatitis: results of an ongoing pilot study
Authors: R. Dobbins, P. Gholam, S. Ertel, N. Furey, G.M. Baskaran, Z. Goodman, D. Oldach, P. Fernandes
Journal: Journal of Hepatology (2017)
Anti-placental growth factor therapy attenuates experimental hepatopulmonary syndrome
Authors: S. Raevens, A. Paridaens, S. Lefere, C. Casteleyn, B. Jonckx, X. Verhelst, H. Van Vlierberghe, C. Van Steenkiste, A. Geerts, L. Devisscher, I. Colle
Journal: Journal of Hepatology (2017)
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Authors: Juan-Jose Lahuerta, Bruno Paiva, Maria-Belen Vidriales, Lourdes Cordón, Maria-Teresa Cedena, Noemi Puig, Joaquin Martinez-Lopez, Laura Rosiñol, Norma C. Gutierrez, María-Luisa Martín-Ramos, Albert Oriol, Ana-Isabel Teruel, María-Asunción Echeveste, Raquel de Paz, Felipe de Arriba, Miguel T. Hernandez, Luis Palomera, Rafael Martinez, Alejandro Martin, Adrian Alegre, Javier De la Rubia, Alberto Orfao, María-Victoria Mateos, Joan Blade, Jesus F. San-Miguel
Journal: Journal of Clinical Oncology (2017)

Purpose To perform a critical analysis on the impact of depth of response in newly diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Español de Mieloma) 2000 and GEM2005MENOS65 studies for transplant-eligible MM and the GEM2010MAS65 clinical trial for elderly patients with MM who had minimal residual disease (MRD) assessments 9 months after study enrollment. Median follow-up of the series was 71 months. Results Achievement of complete remission (CR) in the absence of MRD negativity was not associated with prolonged progression-free survival (PFS) and overall survival (OS) compared with near-CR or partial response (median PFS, 27, 27, and 29 months, respectively; median OS, 59, 64, and 65 months, respectively). MRD-negative status was strongly associated with prolonged PFS (median, 63 months; P < .001) and OS (median not reached; P < .001) overall and in subgroups defined by prior transplantation, disease stage, and cytogenetics, with prognostic superiority of MRD negativity versus CR particularly evident in patients with high-risk cytogenetics. Accordingly, Harrell C statistics showed higher discrimination for both PFS and OS in Cox models that included MRD (as opposed to CR) for response assessment. Superior MRD-negative rates after different induction regimens anticipated prolonged PFS. Among 34 MRD-negative patients with MM and a phenotypic pattern of bone marrow involvement similar to monoclonal gammopathy of undetermined significance at diagnosis, the probability of "operational cure" was high; median PFS was 12 years, and the 10-year OS rate was 94%. Conclusion Our results demonstrate that MRD-negative status surpasses the prognostic value of CR achievement for PFS and OS across the disease spectrum, regardless of the type of treatment or patient risk group. MRD negativity should be considered as one of the most relevant end points for transplant-eligible and elderly fit patients with MM.
Prevalence and genotype distribution of hepatitis C virus in Georgia: a 2015 nationwide population-based survey
Authors: D. Baliashvili, A. Kasradze, G. Kuchukhidze, S. Salyer, A. Gamkrelidze, K. Zakhashvili, M. Alkhazashvili, G. Chanturia, N. Chitadze, R. Sukhiashvili, M. Shakhnazarova, P. Imnadze, J. Drobeniuc, C. Blanton, S. Russell, J. Morgan, F. Averhoff, L. Hagan
Journal: Journal of Hepatology (2017)
The prenylation inhibitor lonafarnib can induce post-treatment viral clearance in patients with chronic delta hepatitis resulting in alt normalization and regression of fibrosis
Authors: C. Yurdaydin, R. Idilman, C. Kalkan, M.F. Karakaya, A. Caliskan, O. Keskin, E. Yurdcu, S.C. Karatayli, M. Bozdayi, C. Koh, T. Heller, J. Glenn
Journal: Journal of Hepatology (2017)
Effect of hepatitis C treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on patient’s health related quality of life: analysis of Phase 3a and phase 3b clinical trials
Authors: S. Saab, D. Mehta, S. Hudgens, N. Grunow, Y. Bao, B. Pinsky
Journal: Journal of Hepatology (2017)
The immunomodulatory activity of the protease-inhibitor SerpinB3 in vivo and in vitro
Authors: A. Cappon, S. Quarta, A. Biasiolo, C. Turato, G. Villano, M. Ruvoletto, S. Sutti, S. Bruzzi, E. Novo, E. Morello, S. Cannito, E. Albano, M. Parola, P. Pontisso
Journal: Journal of Hepatology (2017)
Body cameras on staff reduced attacks in psychiatric wards, finds study
Authors: Zosia Kmietowicz
Journal: BMJ (2017)

A mental health unit where staff members wore body cameras saw incidents involving emergency restraint halve over three months and complaints drop, a pilot study has found. Violent incidents also decreased on three of the five wards studied, though incidents of verbal abuse increased.

Alex O’Neill-Kerr, clinical medical director at Northamptonshire Healthcare NHS Foundation Trust, said that if larger studies showed similar results then the scheme could be rolled out to psychiatric units across the country.

“Improving patient and staff safety, coupled with improving the quality of care afforded, are key priorities for us,” he said, “and we are always striving to find innovative ways to achieve those objectives. As this …
Nonalcoholic fatty liver with hepatic arterial buffer response strongly caused metabolic diseases, while bright pancreas was not associated with metabolic diseases – 5 years’ cohort
Authors: M. Hirooka, Y. Koizumi, T. Miyake, A. Yukimoto, Y. Nakamura, Y. Imai, T. Watanabe, O. Yoshida, Y. Tokumoto, M. Abe, Y. Hiasa
Journal: Journal of Hepatology (2017)
The systemic inflammatory response is a prognostic marker in human immunodeficiency virus-infected patients with hepatocellular carcinoma
Authors: D.J. Pinato, M. Merli, A.D. Pria, S. Jamshaid, K. Parker, N. Pagani, H. Hasson, C. Uberti-Foppa, E. Messina, R. Sharma, M. Nelson, M. Bower
Journal: Journal of Hepatology (2017)
Exosome derived from palmitic acid-treated hepatocytes activates hepatic stellate cells
Authors: Y.-S. Lee, E. Ko, Y.J.Y. Yoo, J. Je, S.J. Suh, Y.K. Jung, J.H. Kim, Y.S. Seo, H.J. Yim, J.E. Yeon, K.S. Byun
Journal: Journal of Hepatology (2017)
Assessment of gastro-oesophageal reflux symptoms in children
Authors: S Farrell, C Renfrew, MD Shields, WA McCallion
Journal: Endoscopy (2005)

Introduction: Symptom scores in adult gastro-oesophageal reflux (GOR) are well established. Children however have difficulty expressing symptoms such as heartburn. Our aim was to prospectively examine whether symptom scores could predict the presence of GOR in children.
Insulin/IGF-1 receptors mediate acquired resistance to anti-EGFR therapy in human cholangiocarcinoma cells
Authors: J. Vaquero, C. Lobe, S. Tahraoui, A. Clapéron, M. Mergey, D. Wendum, F. Merabtene, C. Desbois-Mouthon, F. Praz, L. Fouassier
Journal: Journal of Hepatology (2017)
Current treatment options for hepatitis C virus/human immunodeficiency virus patients: the experience of the scolta project
Authors: B. Menzaghi, E. Ricci, C. Magni, G. Parruti, L. Nicolini, G. Cenderello, F. Peruzzu, M. Gussio, R. Gulminetti, P. Bonfanti
Journal: Journal of Hepatology (2017)
Survher: A retrospective multicenter study comparing demographic and tumor characteristics of clinical trials versus clinical practice patients with HER2-positive breast cancer.
Authors: Grazia Arpino, Mauro Truini, Filippo Montemurro, Francesco Schettini, Andrea Michelotti, Stefania Russo, Raffaella Palumbo, Marina Elena Cazzaniga, Claudio Zamagni, Vito Lorusso, Dario Bruzzese, Ferdinando Riccardi, Michelino De Laurentiis, Angelo Di Leo, Alessandra Beano, Alberto Zaniboni, Antonio Nuzzo, Maria Malagoli, Domenico Bilancia, Sabino De Placido
Journal: Journal of Clinical Oncology (2014)

640 Background: Several clinical trials (CT) have shown remarkable efficacy of trastuzumab-based adjuvant therapy in human epidermal growth factor receptor 2 (HER2)-positive breast cancers (BC). However, CT patient population may not always be representative of patients routinely seen in clinical practice (CP). The aim of this study was to compare clinical and tumoral features between CT and CP patients with HER2 positive BC. Methods: From January to December 2012, 696 consecutive patients with HER2+ early BC, treated in 36 Italian Hospitals were enrolled in our study. Age, treatment information, tumor size (T), nodes (N), grade (G), estrogen receptor (ER) and progesterone receptor (PgR) status, were prospectively collected in CP patients. In parallel, the same data were extracted from the adjuvant trastuzumab trials FNCLCC-PACS-04, BCIRG-006, FinHER, HERA, NSABP B31-NCCTG N9831 and pooled using the random-effects model of DerSimonian and Laird. CT and CP groups were compared by using the Cochran Q statistics. Results: Compared to CT patients, CP patients were more likely to be older than 50 years (65% vs 48%, respectively, p<0.0001) and have ER positive (71% vs 51%, p<0.0001) and PgR positive (60% vs 39%; p<0.0001) BC and were less likely to have tumor bigger than 2 cm (T ≥2 cm 39% vs 59%; p<0.0001), with positive N (47% vs 89%, p<0.0001) and high G (61% vs 67%, p=0.0241). Additionally, CP patients received more frequently adjuvant endocrine therapy (70% vs 57% p<0.0003) and less frequently adjuvant chemotherapy (97% vs 99.7%; p<0.0001). Among chemo-treated patients there was no difference in the type of administered chemotherapy. Conclusions: Most tumor and clinical characteristics significantly differed among CP and CT patients. These data raise doubts about the applicability of CT results to the CP patient population. Therefore, assessing the efficacy and tolerability of anti-cancer treatments also in a clinical scenario closer to the routine CP may be needed to further validate CT results.
Search for anti-hepatitis C virus positive patients lost in the health system: analysis of the absence of referring and the abandonment of the patient
Authors: E.M. Crespo, F.C. Espinosa, A. Lue, R.B. Ruesca, S.L. Perez, E.S. Villacampa, T.S. Aullo
Journal: Journal of Hepatology (2017)
Methodological Guidelines to Study Extracellular Vesicles
Authors: Frank A.W. Coumans, Alain R. Brisson, Edit I. Buzas, Françoise Dignat-George, Esther E.E. Drees, Samir El-Andaloussi, Costanza Emanueli, Aleksandra Gasecka, An Hendrix, Andrew F. Hill, Romaric Lacroix, Yi Lee, Ton G. van Leeuwen, Nigel Mackman, Imre Mäger, John P. Nolan, Edwin van der Pol, D. Michiel Pegtel, Susmita Sahoo, Pia R.M. Siljander, Guus Sturk, Olivier de Wever, Rienk Nieuwland
Journal: Circulation Research (2017)

Owing to the relationship between extracellular vesicles (EVs) and physiological and pathological conditions, the interest in EVs is exponentially growing. EVs hold high hopes for novel diagnostic and translational discoveries. This review provides an expert-based update of recent advances in the methods to study EVs and summarizes currently accepted considerations and recommendations from sample collection to isolation, detection, and characterization of EVs. Common misconceptions and methodological pitfalls are highlighted. Although EVs are found in all body fluids, in this review, we will focus on EVs from human blood, not only our most complex but also the most interesting body fluid for cardiovascular research.
A new strategy to improve the liver engraftment efficiency of transplanted human biliary tree stem/progenitor cells: cell coating with hyaluronic acid
Authors: L. Nevi, G. Carpino, V. Cardinale, D. Costantini, S.D. Matteo, S. Safarikia, F. Melandro, P.B. Berloco, L. Reid, E. Gaudio, D. Alvaro
Journal: Journal of Hepatology (2017)
Development of a Triazolyldisulfide Compound That Increases the Affinity of Hemoglobin for Oxygen and Reduces Hypoxic Sickling of Sickle Cells
Authors: Akito Nakagawa, Ferrari Michele, Chen Liu, Lorenzo Berra, Elizabeth S. Klings, Martin K. Safo, Donald B. Bloch, Osheiza Abdulmalik, Warren M. Zapol
Journal: Blood (2016)
Abstract PR04: Small molecule-mediated activation of Ras elicits inhibition of MAPK and PI3K signaling though pathway feedback
Authors: Jennifer E. Howes, Denis T. Akan, Bethany M. Alicie, Alex G. Waterson, Olivia W. Rossanese, Stephen W. Fesik
Journal: Clinical Cancer Research (2017)

Abstract Oncogenic mutation or hyper-activation of Ras results in aberrant cellular signaling and is responsible for approximately 30% of all human tumors. Therefore, Ras is an outstanding candidate for therapeutic inhibition. However, the discovery of potent inhibitors has been challenging. Our laboratory has recently discovered small molecules that perturb Son of Sevenless (SOS) -catalyzed nucleotide exchange on Ras (Burns et al. PNAS 2014). Here we describe experiments conducted to determine the mechanism of compound action. SOS activator compound 4 (C4) induces signaling flux through the MAPK pathway in response to elevated Ras-GTP levels, reminiscent of epidermal growth factor signaling. We used mass spectrometry to show that in response to C4 stimulation, phospho-modifications on SOS1 increased at ERK phosphorylation consensus sequences. We hypothesize that these phospho-modifications can cause delocalization of SOS and membrane bound Ras, and we are currently using proximity-ligation to assess whether the interaction between SOS1 and Ras is affected by C4 treatment. Cross-talk between the MAPK and PI3K signaling pathways may be responsible for the inhibition of phospho-AKT Ser473 levels in response to MAPK signaling flux, or vice versa. Here we show, using MEK and PI3K inhibitor pre-treatments, that events in both pathways are independent after C4 treatment. As both SOS1 and PI3K bind to Ras at a similar site, we are currently testing the hypothesis that C4 disrupts the interaction between Ras and PI3K, whilst allowing signaling flux through the MAPK pathway. Overall, we have discovered small-molecule activators of SOS that modulate Ras-GTP levels, resulting in signaling flux through the MAPK pathway and eventual downstream inhibition of both the MAPK and PI3K pathways in cancer cells. This abstract is also being presented as Poster A15. Citation Format: Jennifer E. Howes, Denis T. Akan, Bethany M. Alicie, Alex G. Waterson, Olivia W. Rossanese, Stephen W. Fesik. Small molecule-mediated activation of Ras elicits inhibition of MAPK and PI3K signaling though pathway feedback. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr PR04.
Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients.
Authors: Sukhbinder K. Dhesy-Thind, Brandon Matthew Meyers, Humaid Obaid Al-Shamsi, Alexandra Papaioannou, Kevin M. Zbuk, Gregory Russell Pond
Journal: Journal of Clinical Oncology (2013)

e20522 Background: Frailty is traditionally assessed by a comprehensive geriatric assessment (CGA); there is no agreed upon standard for a CGA, and it is not feasible to implement in routine oncology practice. In contrast, the Edmonton Frailty Scale (EFS) is a simple questionnaire, requiring less than 5 minutes to complete, initially validated as a surrogate to the CGA in general medicine patients (Rolfson et al, 2006). We conducted a pilot study to establish if the EFS would add utility beyond clinician’s expertise. Methods: The EFS was administered to stage II-IV CRC patients ≥70 years, referred to a Medical Oncologist at a tertiary care centre. The EFS was completed by one of the investigators, with the treating oncology team blinded to results, and follow up of 14 months. Results: Forty-six patients were enrolled with the following characteristics: average age 76, 48% male, and 78% Zubrod performance status (PS) 0-1. The EFS was reproducible between visits (r = 0.81 [95%CI 0.64-0.9], p&lt;0.01). No association existed for the EFS and receipt of chemotherapy for the study population as a whole, however none of the stage II patients had features requiring chemotherapy. Restricting the analysis to stage III/IV patients demonstrated a reduced likelihood of receiving chemotherapy with higher EFS scores (Odds ratio 0.56 per unit increment [95%CI 0.37-0.85] p&lt;0.01). A similar effect was observed after multivariate analysis (adjusting for PS, age, stage and gender, Odds ratio 0.41 per unit increment [95%CI 0.18-0.96] p&lt;0.05). The clinician’s qualitative impression was associated with the EFS (p&lt;0.01). No association existed between the EFS and upfront dose reductions, choice of less toxic regimens, or hospitalization secondary to grade 3/4 toxicities. Conclusions: The EFS can identify patients that Oncologists may have thought were too frail for chemotherapy, independent of PS. The EFS has the potential to add a reproducible, and quantifiable measure of frailty to aid in decision making in oncology practice.
Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: the Rotterdam Study
Authors: L.J.M. Alferink, K. Trajanoska, J.D. Schoufour, P. Taimr, A.M. Ikram, H.L.A. Janssen, H.J. Metselaar, F. Rivadeneira, S.D. Murad
Journal: Journal of Hepatology (2017)